Study	Reason for exclusion
Asbury 1998	A phase II trial of amonafide in patients with mixed mesodermal tumours of the uterus. Amonafide‐a drug that acts through intercalation of tumour DNA‐was used to treat 16 patients who had measurable, advanced mixed mesodermal tumours of the uterus. The starting dose was 300 mg/m2 intravenously over 1 hour for 5 consecutive days every 3 weeks. Outcome: This dose schedule was associated with poor response rate and substantial toxicity. No comparison group.
Currie 1996	Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP‐16). Outcome: Hydroxyurea, dacarbazine (DTIC), and etoposide (VP‐16) shows moderate activity in patients with advanced or recurrent carcinosarcoma. No comparison group.
Curtin 2001	Phase II study of paclitaxel in patients with advanced or recurrent uterine carcinosarcoma who failed to respond to local therapy. Outcome: Overall, paclitaxel shows 18.2% response rate in patients with uterine carcinosarcoma. No comparison group.
Fowler 2002	Phase II group‐wide study of the Gynecologic Oncology Group to determine the toxicity and objective response rate of trimetrexate (TMTX) in patients with advanced, persistent, or recurrent mixed mesodermal tumours of the uterus. Outcome: Oral TMTX has insignificant activity in uterine carcinosarcoma. No comparison group.
Miller 2005	Phase II trial of topotecan at a target dose of 1.5 mg/m2 was administered IV daily for 5 days, every 3 weeks, in persistent or recurrent carcinosarcoma of uterus. Outcome: Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent uterine. carcinosarcoma previously treated with chemotherapy. No comparison group.
Perez 1979	Retrospective study of 54 patients with uterine carcinosarcoma, patients with stage I‐II were treated with surgery alone or pre‐operative intracavity irradiation, or combination of pre‐operative intracavity irradiation and external irradiation. Patients with stage III‐IV were treated with surgery alone or combination of surgery and post operative irradiation or irradiation alone. Outcome: Patients with stage I‐II treated with pre‐operative irradiation showed reduced pelvic recurrence rate. None of patients with stage III‐IV survived.
Powell 2010	Retrospective study of 46 eligible patients with advanced stage (III or IV), persistent or recurrent uterine carcinosarcoma (Malignant mixed Mullerian tumour) and no prior chemotherapy. Patients received paclitaxel at 175 mg/m2 intravenously (IV) over 3 hours plus carboplatin IV over 30 minutes every 3 weeks until disease progression or adverse effects occurred. No comparison group.
Ramondetta 2003	A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine carcinosarcoma. Outcome: None of the patients had complete response, there was partial response in two and stable disease in one patient. Partial response duration was 6 and 9 months. No comparison group.
Resnik 1995	Phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in Mixed Mullerian Tumors (MMT) of the uterus, in 54 patients, 23 with early stage I‐II, and 19 with stage III‐IV. Outcome: median survival was 18 months. No comparison group.
Sutton 1989	Phase II trial of ifosfamide and mesna in mixed mesodermal tumours of the uterus. Outcome: Response rate of 32% with 17.9% showing complete response. No comparison group.
Sutton 2005	Study on adjuvant ifosfamide and cisplatin after primary surgery for stage I or II carcinosarcoma of the uterus. Ifosfamide was given at 1.5g/m2 I.V, 20mg/m2 cisplatin, followed by 120mg/m2 mesna for five days every 21 day for 3 cycles. Outcome: Two years progression‐free survival was 69% and overall survival was 82%. The five year overall survival was 62%. No comparison group.
Toyoshima 2004	A retrospective review of six patients with uterine carcinosarcoma treated with paclitaxel and carboplatin. Outcome: Four patients had complete response and two had progressive disease. Median progression‐free survival was 18 months, median overall survival was 25 months. No comparison group.

DTIC: hydroxyurea, dacarbazine
 TMTX: trimetrexate